Amphetamine Stimulant Prodrug denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for amphetamine stimulant prodrug are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issues Duplicate-Therapy Denials for Amphetamine Stimulant Prodrugs

Cigna's pharmacy systems flag a claim as duplicate therapy when another drug in the same pharmacological class — typically another amphetamine salt or stimulant formulation — appears on the patient's active medication list or recent claims history. This is an automated clinical-edit trigger, not a human clinical judgment. The denial does not mean both medications are wrong; it means the system requires a human review to confirm that concurrent use is clinically intentional and appropriate. These denials are among the most straightforward to reverse when the prescriber responds clearly.

## Why This Denial Is Appealable

Duplicate-therapy denials are adverse benefit determinations subject to ERISA §503 (employer-sponsored plans) and ACA §2719 (marketplace and fully-insured plans) appeal rights. The internal appeal process typically resolves these quickly because the reviewer simply needs to understand the clinical rationale for concurrent or transitional use. If the internal appeal fails, independent external review by an IRO is available. The external-review window is approximately four months from the denial notice; expedited review is available when delay poses a health risk.

## The Concrete Appeal Process

1. Identify the conflicting medication. Request from Cigna the specific drug that triggered the duplicate edit — this determines your appeal strategy. 2. Determine the clinical situation: Is this a planned transition (tapering off one while starting another), concurrent therapy for distinct indications, or an administrative error (the old prescription was stopped but not updated in the system)? 3. File the internal appeal with a clear prescriber explanation of the clinical intent. 4. If administrative: Cancel the outdated prescription in the system and resubmit the claim before filing a formal appeal.

## Documentation to Gather

• Current medication list: A reconciled list showing which agent is being discontinued and the transition timeline, or a clinical explanation for concurrent use.
• Prescriber explanation letter: Addresses precisely why both medications appear in the record and what the clinical plan is. This is the single most important document for duplicate-therapy appeals.
• Chart notes supporting the rationale: If the duplicate is intentional (e.g., bridging during a formulation switch), document the clinical reasoning in the chart.
• Pharmacy records: Showing fill dates and quantities to demonstrate there is no actual overlap of active use if the denial was triggered by a stale prescription.

## Criteria-Mapping Strategy

Pull Cigna's duplicate-therapy or drug-interaction edit policy and address the specific clinical edit that was triggered. Map each concern raised in the denial to a specific chart fact or prescriber statement that resolves it. Because these denials are often automated, a concise, well-organized response that directly answers "why are two drugs in this class present" is more effective than a lengthy narrative.